ArticleFrontiers in pediatrics2026
Sotatercept administration in a young infant with severe pulmonary arterial hypertension: A case report.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary arterial hypertension (PAH) in infants is a rare, life-threatening condition characterized by elevated pulmonary artery pressure resulting from endothelial dysfunction, vasoconstriction, and vascular remodeling. The treatment options are limited, and the prognosis is poor. In children, 5-year survival following diagnosis remains suboptimal, with estimates of approximately 74% despite advances in therapy. Unfortunately, many patients continue to experience clinical decline despite optimized medical regimens, highlighting the need for novel therapeutic approaches. Sotatercept, an activin receptor type IIB fusion protein, is a new therapeutic agent that modulates the signaling pathway of the transforming growth factor-beta superfamily. It enhances bone morphogenetic protein receptor type 2 signaling, thereby improving pulmonary vascular remodeling and promoting vasodilation. In adult clinical trials, sotatercept has demonstrated improvements in pulmonary vascular resistance, functional capacity, and biomarkers such as brain natriuretic peptide, while reducing the risk of clinical worsening or death, and it was recently approved by the FDA for use in adults to improve exercise capacity and the World Health Organization (WHO) functional class. Despite promising results in adults, data on the use of sotatercept in pediatric patients remain extremely limited and nonexistent for children <1 year of age. Herein, we report the first known use of sotatercept in an infant with severe, treatment-refractory PAH. Treatment was associated with clinical and echocardiographic improvement through 1 year of follow-up, supporting the potential role of sotatercept as an adjunctive therapy in pediatric PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.